Show simple item record

dc.contributor.authorvon Itzstein, Mitchell S
dc.contributor.authorKhan, Shaheen
dc.contributor.authorPopat, Vinita
dc.contributor.authorLu, Rong
dc.contributor.authorKhan, Saad A
dc.contributor.authorFattah, Farjana J
dc.contributor.authorPark, Jason Y
dc.contributor.authorBermas, Bonnie L
dc.contributor.authorKarp, David R
dc.contributor.authorAhmed, Murtaza
dc.contributor.authorSaltarski, Jessica M
dc.contributor.authorGloria-McCutchen, Yvonne
dc.contributor.authorXie, Yang
dc.contributor.authorLi, Quan-Zhen
dc.contributor.authorWakeland, Edward K
dc.contributor.authorGerber, David E
dc.date.accessioned2020-06-02T23:58:17Z
dc.date.available2020-06-02T23:58:17Z
dc.date.issued2020
dc.identifier.issn1083-7159
dc.identifier.doi10.1634/theoncologist.2019-0911
dc.identifier.urihttp://hdl.handle.net/10072/394330
dc.description.abstractImmune-related adverse events induced by immune checkpoint inhibitor (ICI) therapy may affect diverse organ systems, including skeletal and cardiac muscle. ICI-associated myositis may result in substantial morbidity and occasional mortality. We present a case of a patient with advanced non-small cell lung cancer who developed grade 4 myositis with concurrent myocarditis early after initiation of anti-programmed death ligand 1 therapy (durvalumab). Autoantibody analysis revealed marked increases in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody levels that preceded clinical toxicity, and further increased during toxicity. Notably, the patient had a history of intolerable statin myopathy, which had resolved clinically after statin discontinuation and prior to ICI initiation. This case demonstrates a potential association between statin exposure, autoantibodies, and ICI-associated myositis.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAlphamed Press
dc.relation.ispartofjournalOncologist
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3211
dc.titleStatin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationvon Itzstein, MS; Khan, S; Popat, V; Lu, R; Khan, SA; Fattah, FJ; Park, JY; Bermas, BL; Karp, DR; Ahmed, M; Saltarski, JM; Gloria-McCutchen, Y; Xie, Y; Li, Q-Z; Wakeland, EK; Gerber, DE, Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?, Oncologist, 2020
dcterms.dateAccepted2020-04-16
dc.date.updated2020-06-02T05:45:07Z
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.hasfulltextNo Full Text
gro.griffith.authorVon Itzstein, Mitchell S.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record